Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. The company is focused on developing treatments for cystic fibrosis (CF), a life-threatening genetic disease, and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), life shortening inherited blood disorders. Our pipeline includes clinical-stage programs in CF, sickle cell disease, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. It has four commercial drugs -- TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO -- used to treat CF. While the US generates some 60% of the company's revenue, Vertex's medicines are sold in some part of North America, Europe, and Australia.

Pharmaceutical and Medicine Manufacturing; Scientific Research and Development Services; Chemical Manufacturing; Manufacturing

Pharmaceutical Preparations; Commercial Physical Research; Chemicals and Allied Products; Manufacturing

$9870M